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Estetrol (E4) is a natural human estrogen that is present at high concentrations during
pregnancy. E4 has been reported to act as an endogenous estrogen receptor modulator,
exerting estrogenic actions on the endometrium or the central nervous system but
presenting antagonistic effects on the breast. Due to these characteristics, E4 is currently
being developed for a number of clinical applications, including contraception and
menopausal hormone therapy. Endothelial nitric oxide (NO) is a key player for vascular
function and disease during pregnancy and throughout aging in women. Endothelial NO
is an established target of estrogens that enhance its formation in human endothelial cells.
We here addressed the effects of E4 on the activity and expression of the endothelial
nitric oxide synthase (eNOS) in cultured human umbilical vein endothelial cells (HUVEC).
E4 stimulated the activation of eNOS and NO secretion in HUVEC. E4 was significantly
less effective compared to E2, and a peculiar concentration-dependent effect was found,
with higher amounts of E4 being less effective than lower concentrations. When E2
was combined with E4, an interesting pattern was noted. E4 antagonized NO synthesis
induced by pregnancy-like E2 concentrations. However, E4 did not impede the modest
induction of NO synthesis associated with postmenopausal-like E2 levels. These results
support the hypothesis that E4 may be a regulator of NO synthesis in endothelial cells
and raise questions on its peculiar signaling in this context. Our results may be useful
to interpret the role of E4 during human pregnancy and possibly to help develop this
interesting steroid for clinical use.
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Introduction
Estetrol [estra-1,3,5(10)-triene-3,15α, 16α, 17β-tetrol] is an estrogenic hormone discovered in
1965 by Diczfalusy and co-workers at the Karolinska Institute in Stockholm (1, 2). E4 is produced
exclusively by the human fetal liver during pregnancy. It is present in fetal blood and reaches
maternal circulation through the placenta and can be detected in amniotic fluid and maternal urine
(3–6). E4 concentrations increase exponentially during pregnancy and peak at term with fetal levels
about 10–20 times higher than in the mother. After delivery, blood levels of E4 become rapidly
undetectable (7–9).
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The pharmacological properties of E4 have been intensely
investigated, but yet the physiological function of E4 has not been
clearly understood. For example, in contrast with E2, E4 does
not stimulate nor binds to sex hormone-binding globulin (SHBG)
(10) and also does not inhibit the activity of cytochrome P450
liver enzymes; it is only minimally metabolized and completely
excreted in the urine unaltered (11). E4 has a long half-life in
humans, with an average of 28 h, which is about twofold longer
than E2 (12).
E4 has a low to moderate affinity for both human estrogen
receptor alpha (ER alpha) and ER beta with a four/fivefold pref-
erence for ER alpha (11). Based on this relatively low receptor
binding affinity compared to E2, E4 was originally thought to be a
weak estrogen (13). Subsequently, it was found that in rats, E4 acts
as an estrogen on bone, brain, vagina, and endometrium (14, 15).
However, it surprisingly acts as an estrogen antagonist on the rat
breast DMBA model, where it prevents the development of new
breast tumors and stimulates the regression of pre-existing ones
(16, 17). The estrogen-antagonistic effect of E4 in the breast has
been further supported by the observation of the ability of this
steroid to decrease the stimulatory effect of E2 on cytoskeletal
rearrangement, horizontal migration, andmatrix invasion of ER+
T47-D human breast cancer cells (18).
The role of estrogens on the cardiovascular system has been
largely studied. Estrogens promote vasodilatation, endothelial
remodeling, and repair and counteract atherosclerosis (19). A key
mechanism of action of estrogens in the cardiovascular system
stays in the regulation of nitric oxide (NO) synthesis in endothelial
cells (20–24).
Nitric oxide is a central controller of vascular function; it is a
vasoactive molecule primarily produced by the vascular endothe-
lium that exerts vascular-protective and anti-atherogenic effects
on the vessel wall. NOdecreases platelet aggregation and adhesion
to the endothelium (25), limits vascular smooth muscle prolifer-
ation (26), inhibits neointima formation (27), prevents monocyte
chemotaxis (28), and inhibits leukocyte adhesion to the endothe-
lium by transcriptionally reducing adhesion molecule expression
(29). Endothelial nitric oxide is produced by the endothelial nitric
oxide synthase (eNOS) isoform upon conversion of the substrate
-arginine to -citrulline (30). More recently, NO has been iden-
tified as a key agent in maintaining fetal oxygenation through the
regulation of feto-placental blood flow. This is true in normal and
even more in pregnancies where fetal oxygen delivery fails, such
as during fetal growth restriction (31, 32).
Wehere characterized the effects of E4 onhumanumbilical vein
endothelial cells (HUVEC), and specifically on eNOS activity and
NO synthesis. Furthermore, we addressed the possible regulatory
role of E4 on E2-related NO synthesis.
Materials and Methods
Cell Culture and Treatments
Human umbilical vein endothelial cells were obtained from
umbilical veins from healthy women at the time of delivery.
Written informed consent was obtained from each patient in
accordance with the declaration of Helsinki. After collection, the
umbilical cord was rapidly immersed in sterile saline solution
and immediately processed for endothelial cell isolation. Under a
laminar flow sterile hood, the umbilical vein was cannulated and
thoroughly rinsed with sterile saline solution. After clamping the
other extremity, the vein was filled for 30min with 1mg/mL type
IA collagenase (Sigma-Aldrich, USA) pre-warmed at 37°C. The
action of the collagenase solution was blocked with DMEM 10%
FBS, the collected solutions were centrifuged at 4°C for 30min at
1300 rpm, the supernatant was discarded, and the cell pellet was
gently resuspended in phenol red-free DMEM (Gibco, Thermo
Fisher Scientific) contained 10% FBS (Lonza Walkersville, Inc.),
antibiotic–antimycotic (Gibco, Thermo Fisher Scientific), 2mM
-glutamin (Gibco, Thermo Fisher Scientific), 25mM HEPES
(Gibco, Thermo Fisher Scientific), 0.2μg/mL human epidermal
growth factor (Sigma-Aldrich, USA), and 50U/mL heparin. The
cells were then plated on culture plates pre-coated with 1% sterile
gelatin. All cell cultures were maintained in a humidified 5%
CO2 atmosphere at 37°C and were grown to confluence and used
between passage 3 and 4. Endothelial cell purity is extremely high
after passage 2, due to elimination of contaminating macrophages
and smoothmuscle cells through replating. In confluent HUVEC,
cell proliferation rate is negligible due to contact inhibition. Cell
count and trypan blue exclusion were used to assess in pre-
liminary experiments whether the experimental treatment may
result in modified cell proliferation or death rates, and no sig-
nificant changes were noted. Before experiments, medium was
replaced for 24 h with steroid-deprived FBS (Lonza Walkersville,
Inc.) and, when the inhibition treatment was required, the active
treatments were done 30min afterwards it. Control cells always
received the same amount of ethanol (solvent for E2/E4, 0.01%
final concentration). Estetrol was kindly provided by Herjian
Coelingh Bennink (Pantarhei Biosciences), 17β-estradiol was
from Sigma-Aldrich, USA-Aldrich, and ICI 182,780 from Tocris
Cookson, UK.
Endothelial Nitric Oxide Synthase Activity Assay
Endothelial nitric oxide synthase activity was determined as con-
version of 3H-arginine to 3H-citrulline in endothelial cell lysates
with NOS assay kit (Calbiochem, Merck-Millipore, Germania).
Briefly, HUVEC cells were harvested in ice-cold PBS and were
pelleted in a microfuge at 13,000 rpm for 10min at 4°C, then were
homogenized in a buffer containing 25mM Tris–HCl, pH 7.4,
1mM EDTA and 1mM EGTA, 1mM DTT, 10μg/mL leupeptin,
2μg/mL aprotinin, and 100μg/mL PMSF. About 0.001mCi 3H-
citrulline was separated with use of an acidic ion-exchange resin,
as described in Ref. (33). Extracts incubated with the eNOS
inhibitor, 1mM N-nitro--arginine methyl ester, were used as
blank. Results were expressed as picomoles of converted citrulline
per milligram of assayed protein extracts.
Nitrite Assay
Nitric oxide production was determined as the overall amount
of stable NO metabolites, nitrites, released in the cell culture
medium during treatment. Briefly, the fluorescent product 1H-
naphthotriazole was measured in the cell culture medium with
excitation/emission wavelengths of 365 and 450 nm and was
formed by the reaction of nitrosonium cation that forms spon-
taneously NO and 2,3-diaminonaphthalene (34). Standard curves
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were constructed with sodium nitrite. Non-specific fluorescence
was determined in the presence of 3mM NG-monomethyl--
arginine.
Immunoblottings
After treatments, cells were collected on ice with lysis buffer con-
taining 50mM Tris–HCl, pH 7.4, 1mM EDTA, 1% IGEPAL, pro-
tease inhibitor cocktail (Sigma-Aldrich, USA), and phosphatase
inhibitor cocktail 3 (Sigma-Aldrich, USA). The concentration of
total proteins was quantified by PierceMicro BCAAssay (Thermo
Fisher Scientific). Samples, containing 25μg of protein, were sep-
arated on 10% SDS-page gels and transferred to a PVDF mem-
brane (Immobilon-P, Millipore). Antibodies against the following
proteins were used: eNOS (Transduction Laboratories, BD Bio-
sciences), Ser1177-p-eNOS (Upstate Biotechnology, USA), Akt
and Thr308-p-Akt (Upstate Biotechnology), ER alpha (sc-8005,
Santa Cruz Biotechnology, USA), and ER beta (sc-390243, Santa
Cruz Biotechnology, USA). Blots were blocked in 5% BSA and
probed with primary antibody at 4°C overnight, then with an
appropriate secondary antibody conjugated to horseradish per-
oxidase (Santa Cruz Biotechnology, USA) at room temperature
for 2 h. Immunodetection of protein bands were visualized using
chemiluminescence and were recorded with a quantitative digital
imaging system (Quantity One, BioRad, USA). Meanwhile, the
membranes were stripped and reproved with anti-actin antibody
(Santa Cruz Biotechnology, USA) to confirm equal amounts of
loaded samples. Densitometric analysis of the proteins bands was
performed using the NIH ImageJ 1.40g software.
Statistical Analysis
Each experimental condition was reproduced in at least three
independent experiments. All data are presented as mean SEM.
Statistical analysis was performed using GraphPad Prism 5. Sta-
tistical differences between means were analyzed using one-way
ANOVA followed by Bonferroni post-test. Differences at p< 0.05
were considered significant.
Results
E4 Increases eNOS Expression/Activity and NO
Synthesis via ERs in HUVEC
To test the effects of E4 on endothelial NO level, we measured NO
release in the cell culturemediumaswell as cellular expression and
enzymatic activity of eNOS. HUVEC were treated for 48 h, with
increasing concentration of E4 alone representing the physiologi-
cal levels of E4 throughout pregnancy, or in combination with E2.
E4 significantly induced the production of NO and eNOS enzy-
matic activity (Figure 1A). Protein levels of eNOS (Figure 1C) and
of its phosphorylated active form (Figure 1D) were also increased
during exposure to E4. However, E4 was significantly less effec-
tive compared to equimolar amounts of E2 (Figures 1A,C,D).
Surprisingly, we did not find a linear relationship between the
amount of E4 administered and the response in terms of NO
synthesis, eNOS activity or eNOS expression, or phosphorylation.
Indeed, the concentration–effect curve of E4 was bell-shaped,
with increasing doses resulting in lower stimulation.
When HUVEC were treated with the pure estrogen receptor
antagonist ICI 182,780, E4 effects were significantly reduced,
suggesting that E4 acts at least in part via estrogen receptor recruit-
ment (Figures 1A,C,D). ER alpha and ER beta are expressed in
cultured HUVEC as shown by comparative western analysis with
T47-D breast cancer cells and immortalized T lymphocyte Jurkat
cells (Figure 1B).
Interestingly, the effects of an early-pregnancy-like concen-
tration of E2 (10 8M) on NO synthesis as well as on cellular
expression and enzymatic activity of eNOS and p-eNOS were
significantly reduced when HUVEC were co-treated with E4
(Figures 1A,C,D). Inhibition of E2-dependent actions was related
to the amount of E4 added (Figures 1A,C,D).
Differential Regulatory Actions of E4 on
E2-Induced NO Production and eNOS Expression
Based on the Relative Concentrations of the Two
Steroids
Since in women concentration of E2 varies throughout repro-
ductive life, three different concentrations of E2, mimicking
early pregnancy (10 8M), follicular phase (10 9M), or post-
menopause (10 10M) were used to study how NO production
and eNOS expression are influenced in these three settings by E4.
HUVEC were treated for 48 h, with E2 alone or in combination
with increasing amounts of E4.
Addition of E4 to E2-treated cells resulted in a differential
blockade of E2-dependent effects, but the extent of this action
varied based on both E2 and E4 amounts. Indeed, when growing
amounts of E4 were added to pregnancy-like E2 concentrations, a
visible reduction of estradiol-mediated NO synthesis and eNOS
expression was found (Figures 2A,B). On the opposite, when
E4 was added to postmenopausal-like amounts of E2, a non-
significant fall in NO synthesis and a lower reduction of eNOS
expressionwas found (Figures 2A,B). This is particularly interest-
ing, since it suggests that E4 is able to antagonizeNOproduction in
the presence of normal to high levels of E2, but not in the presence
of low amounts, which deserves an explanation.
E4 Modulates NO Synthesis via Rapid
Extranuclear Signaling of ERs
Beyond being able to increase eNOS expression through conven-
tional genomic mechanisms, estrogens also enhance NO synthe-
sis through extranuclear-initiated signaling pathways in HUVEC
(35–37). To assess whether E4 signaling to ERs also recruits this
sort of mechanism, we exposed HUVEC for 30min to E4 or E2.
Rapid E4 administration toHUVEC significantly increasedNO
release in the supernatant along with eNOS enzymatic activity
(Figure 3A). During this type of E4 exposure, rapid phospho-
rylation of eNOS on Ser1177 was observed in the absence of any
increase of eNOS expression (Figure 3B). When compared to
E2, once more, E4 was less potent in this experimental setting
(Figures 3A,B). Similar to the previous findings, increasing the
concentrations of E4 over a 100-fold range did not turn into fur-
ther increases in NO synthesis, eNOS activity nor of Ser1177-eNOS
phosphorylation. On the opposite, a non-significant decrease in
NO release and eNOS activity was noted with increasing E4
concentrations.
Addition of ICI 182,780 dramatically reduced the action of E4,
suggesting that also the rapid extranuclear actions of E4 occur at
least in part via estrogen receptors (Figures 3A,B).
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FIGURE 1 | E4 modulates eNOS during prolonged administration via ER.
Steroid-deprived HUVEC were treated for 48 h with 10 8M E2 or increasing
concentrations of E4 (10 10, 10 9, and 10 8M) in the presence or absence of
the pure estrogen antagonist ICI 182,780 (10 7M). (A) White bars represent
nitrites levels and black bars represent enzymatic activity of eNOS. The
experiments were repeated three times with comparable results. (B–D) Cell
lysates were analyzed by western blotting for ER alpha, ER beta, eNOS, and
Ser1177-p-eNOS. Quantification expressed as meanSEM for three
independent experiments (upper panel) and representative blots are shown
(lower panel). Values in the graph bar were obtained by the ratio of each protein
band versus a loading reference. Significance of the observed effects was
evaluated using one-way ANOVA followed by Bonferroni’s post hoc test
(***p<0.001, *p<0.05 versus control, p<0.001, p<0.01 versus E4,
###p<0.001, #p<0.05 versus E2).
Frontiers in Endocrinology | www.frontiersin.org July 2015 | Volume 6 | Article 1114
Montt-Guevara et al. Estetrol modulates endothelial nitric oxide
con E2
10-8
10-10       10-9         10-8
E2 10-8 + E4 (M)
E2
10-9
E2
10-10
10-10         10-9        10-8
E2 10-9 + E4 (M)
10-10         10-9        10-8
E2 10-10 + E4 (M)
A
con E2
10-8
10-10      10-9         10-8
E2 10-8 + E4 (M)
E2
10-9
E2
10-10
10-10       10-9        10-8
E2 10-9 + E4 (M)
10-10        10-9        10-8
E2 10-10 + E4 (M)
B
ac!n
eNOS
FIGURE 2 | Differential regulatory actions of E4 on E2-induced
NO production and eNOS expression based on the relative
concentrations of the two steroids. Steroid-deprived HUVECs were
treated for 48 h with increasing concentrations of E4 and E2. (A) Bars
represent nitrites levels. The experiments were repeated three times
with comparable results. (B) Cell lysates were analyzed by western
blotting for eNOS. Values in the graph bar were obtained by the ratio of
each protein band with a loading reference. Data are expressed as
meanSEM for three independent experiments. Significance of the
observed effects was evaluated using one-way ANOVA followed by
Bonferroni’s post hoc test (***p<0.001 versus control, ###p<0.001,
##p<0.01 versus E2).
Extranuclear estrogen signaling to eNOS is primarily mediated
by the lipid kinase phosphatidylinositol 3-OH kinase (PI3K) and
by its downstream effector, the serine–threonine kinase Akt (23,
38–40). We therefore assessed whether E4 also uses this signaling
pathway by treating HUVEC for 30min with E4 or E2. While
lower amounts of E4 (10 10M) resulted in increased phosphory-
lation of Akt, further increases in E4 concentrations resulted in
a progressive decrease (Figure 4). Akt phosphorylation related to
low doses of E4 was decreased by ICI 182,780 suggesting that E4
signaling to Akt relies in part on ER recruitment (Figure 4).
Differential Extranuclear Regulatory Actions of
E4 on E2-Induced eNOS and Akt Phosphorylation
Based on the Relative Concentrations of the Two
Steroids
Similar to the previous set of experiments, we tested whether
the modulation by differential combinations of E4 with
pregnancy-like, follicular phase-like, or postmenopausal-like E2
amounts were also present when looking at extranuclear signaling
to eNOS and Akt phosphorylation.
As shown in Figure 5, E4 decreased in a concentration-
dependent manner eNOS and Akt phosphorylation induced by
pregnancy-like amounts of E2, while it did not affect phospho-
rylation of these two targets when co-administered with post-
menopausal amounts of E2 (Figures 5A,B).
Discussion
The main finding of this study is the identification of modulatory
actions of estetrol on nitric oxide synthesis in human endothelial
cells. E4 controls NO synthesis through seemingly complex sig-
naling avenues. Indeed, the responses to increasing amounts of
this steroid are not concentration-dependent. E4 administration
to HUVEC turns into increased NO synthesis both because of
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con E2
10-8
10-10               10-9                 10-8
E4 (M)
ICI
E4 10-9 M
con E2
10-8
10-10            10-9                10-8
E4 (M)
ICI
E4 10-9 M
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FIGURE 3 | E4 rapidly modulates NO synthesis and eNOS enzymatic
activity. Steroid-deprived HUVEC were treated for 30min with 10 8M E2 or
increasing concentrations of E4 in the presence or absence of the estrogen
receptor antagonist ICI (10 7M). (A) White bars represent nitrites levels in
HUVEC and the black bars represent the enzymatic activity of eNOS. The
experiments were repeated three times with comparable results. (B) Cell
lysates were analyzed by western blotting for eNOS and Ser1177-p-eNOS.
Quantification expressed as meanSEM for three independent experiments
(upper panel) and representative blots are shown (lower panel). Values in the
graph bar were obtained by the ratio of eNOS/p-eNOS protein band intensity.
Significance of the observed effects was evaluated using one-way ANOVA
followed by Bonferroni’s post hoc test (***p<0.001 versus control,
p<0.001, p<0.01 versus E4).
enhanced eNOS expression and increased enzymatic activation
through direct phosphorylation on Ser1177. Moreover, estetrol
interferes with 17β-estradiol-dependent NO synthesis, but once
again it does so with a non-conventional behavior. In the pres-
ence of pregnancy-like amounts of E2, E4 blunts NO activation.
However, when lower E2 amounts are present, E4 does not inter-
fere with E2 on NO synthesis. These observations may support
the hypothesis that E4 could be a naturally occurring selective
estrogen receptor modulator, but they also raise questions on its
signaling mechanisms.
Estetrol is an interesting estrogen, produced only by the human
fetal liver during pregnancy, and its physiological role or its mech-
anisms of action are still unknown. The present results suggest that
regulation of vascular endothelial cells in the feto-placental unit
may be a target for this steroid during pregnancy. Activation of
endothelial NO synthesis in the placenta, umbilical vessels, and in
the fetus is key to promote normal fetal development and to allow
fetal adjustment to the stress of delivery (32, 41–43).
con E2
10-8
10-10              10-9               10-8
E4 (M)
ICI
E4 10-9 M
Akt
ac!n
p-Akt
FIGURE 4 | E4 regulates Akt. Steroid-deprived HUVECs were treated for
30min with 10 8M E2 or increasing concentrations of E4 (10 10, 10 9, and
10 8M) in the presence or absence of ICI 182,780 (10 7M). Cell lysates were
analyzed by western blotting for Akt and Thr308-p-Akt. Quantification
expressed as meanSEM for three independent experiments (upper panel)
and representative blots are shown (lower panel). Values in the graph bar were
obtained by the ratio Akt/p-Akt protein band intensity. Significance of the
observed effects was evaluated using one-way ANOVA followed by
Bonferroni’s post hoc test (***p<0.001, **p<0.01, *p<0.05 versus control,
p<0.05 versus E4).
E4 concentrations are about 10-fold higher on the fetal side as
compared to the maternal one. We here find that E4 results in
differential regulation of NO synthesis in endothelial cells based
(a) on its concentration and (b) on the amounts of estradiol
available. This may suggest that the differential amounts of E4 in
the mother and the fetus may result in a selective modulation of
the powerful induction of NO synthesis by estradiol at these two
sites. The high concentrations of E4 found throughout gestation
(ranging between 400 and 1200 pg/mL) may thus represent a
pregnancy-specific way to modulate NO production.
If this were true, it may be envisioned that on thematernal side,
the lower amounts of E4 result in a lower inhibition of the E2-
induced NO synthesis, therefore allowing for efficient vasodilata-
tion toward the fetus. On the contrary, high amounts of E4 on the
fetal side may be helpful to prevent excessive vascular dilatation,
or possibly stimulation of other estrogen targets, such as the fetal
breast. This is consistent with the recent data by Gerard et al.
indicating that E4 antagonizes the stimulatory effects of E2 on
breast glands in an animal model (44), where the antagonistic
actions of E4 are similar in terms of concentration-dependency,
to those we find in human endothelial cells.
While E4 is only found in humans during pregnancy, its pecu-
liar chemical structure makes it interesting for exploitation as an
endocrine tool in a variety of settings. For instance, its suggested
estrogen-antagonistic action in breast tissue, along with its effec-
tiveness in decreasing frequency and intensity of hot flashes (45),
in preventing vulvo-vaginal atrophy (15) and osteoporosis (14),
makes it attractive as a new form ofmenopausal hormone therapy.
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FIGURE 5 | Differential regulatory actions of E4 on E2-induced
eNOS and Akt phosphorylation based on the relative
concentrations of the two steroids. Steroid-deprived HUVECs were
treated for 30min with increasing concentrations of E4 and E2. The total
cell lysates were analyzed by western blotting for Ser1177-p-eNOS (A) and
Thr308-p-Akt (B). Quantification expressed as meanSEM for three
independent experiments (upper panel) and representative blots are shown
(lower panel). Values in the graph bar were obtained by the ratio of each
protein band versus a loading reference. Significance of the observed
effects was evaluated using one-way ANOVA followed by Bonferroni’s
post hoc test (***p<0.001, **p<0.01 versus control, ###p<0.001,
##p<0.01 versus E2).
In this setting, the vascular actions of this steroid become par-
ticularly relevant. Estrogen replacement therapy has been shown
in many studies to exert a vascular-protective action (19, 46),
and most of these effects are attributed to the induction of NO
synthesis in endothelial cells (35, 36, 47–50). Thus, should E4
result in decreased NO synthesis in endothelial cells, this would
be undesirable. To this extent, our results indicate that in the
presence of lower estradiol amounts, similar to those found after
menopause, E4 does not significantly counteract E2-induced NO
synthesis.
Why E4 does not increase eNOS expression and activity or NO
synthesis in a linear concentration-dependent manner is unclear.
Similarly, it is difficult to interpret why interference with NO
synthesis induced by E2 does not happen in the presence of low
estradiol concentrations. Given the high degree of similarity of
cell responses through which E4 induces NO as compared to
E2 (increased eNOS protein expression, increased eNOS activ-
ity, increased phosphorylation of eNOS), it would be tempting
to attribute the interference of E4 with E2 signaling to com-
petitive inhibition for ERs when the two estrogens are jointly
present. To this extent, affinity of E4 for ER alpha is around 100-
fold lower than that of E2 (11). Inhibition of ERs with a pure
ER antagonist (ICI 182,780) blunts some of the effects of E4,
thereby supporting the view that it is at least in part through
ER binding that E4 affects NO synthesis in human endothelial
cells.
However, this does neither seem to explain the peculiar E4
concentration-related responses of HUVEC in terms of NO nor
the non-conventional inhibition of E2-related NO induction.
Other signaling mechanisms may thus be involved, such as
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induction of a shift from the membrane of significant populations
of ERs or alternatively an increased internalization and destruc-
tion of ERs. In a recent manuscript from Abot et al., E4 has been
shown to be able to activate in vivo the ER alpha-dependent sig-
naling that mediate protection from atherosclerosis development,
while failing to activate themembrane-initiated signaling involved
in ER alpha-dependent re-endothelialization and eNOS activation
(51). The authors show that the three-dimensional structure of
ER alpha ligand-binding domain in the presence of E2 or E4 is
very similar, with only a minor shift in the orientation of helix
12 that is not expected to turn into significant modifications in
the interaction with ER-interacting proteins (51). Interestingly,
in the same manuscript, the authors show that both E2 and E4
are able to trigger the protein–protein interaction of ER alpha
with one of its main signaling partners, c-Src. This small adapter
protein is the upstream activator of ER alpha-dependent signaling
to PI3K andMAPK, and is the key initiator ofmembrane-initiated
estrogen signaling to eNOS (22). In the Abot paper, when E2
and E4 were provided together, ER alpha interaction with c-Src
was significantly inhibited below baseline (51). Based on these
observations, it is possible that part of the unexpected effects
of higher concentrations of E4 or the selective inhibition of ER
signaling associated with high but not low E2 concentrations
may be ascribed to the ability of E4 to uncouple the recruitment
of membrane-initiated signaling through interference with ER
alpha/c-Src interaction.
Another potential explanation for the effects of E4 on NO
synthesis in HUVEC may also be provided by parallel signaling
through other receptors. Recently, Gerard et al. have generated
preliminary data supporting the hypothesis that E4 may in part
act via theG protein-coupled estrogen receptor 1 (GPER) in breast
cancer cells (52). Thus, it is possible that interference with other
receptors involved in signaling to eNOS may explain E4 actions
in HUVEC. E4 signaling to eNOS in endothelial cells may thus
represent a useful model to dissect the signaling mechanisms of
this fetal steroid and its biological actions, and will be ground for
future investigation.
In conclusion, our present findings that E4modulates endothe-
lial NO synthesis in HUVEC and that it also interferes with
estradiol induction of NO. It is therefore tempting to speculate
that E4 may represent a naturally occurring compound designed
by nature to control the maternal and fetal vascular actions of
estrogens during gestation.
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